Phase III long-term safety and efficacy of AGN-229666 in patients with seasonal or perennial allergic conjunctivitis
Not Applicable
- Conditions
- Seasonal or perennial allergic conjunctivitis
- Registration Number
- JPRN-UMIN000025876
- Lead Sponsor
- Senju Pharmaceutical co.,ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of allergic hypersensitivity or known hypersensitivity to the study drug or its ingredients 2) History of vernal conjunctivitis or atopic conjunctivitis 3) History of retinal detachment or diabetic retinopathy or presence of any retinal disease that may progress 4) Presence of active ocular disease (bacterial, fungal or viral) or preauricular lymphadenopathy or a positive history of an ocular herpetic infection 5) Under hyposensitization therapy or anticipated use 6) Previously received hyposensitization therapy with negative result in the allergic test at screening
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method